News|Articles|October 23, 2026

Osmoprotection for a more stable tear film in moderate-to-severe dry eye disease

Author(s)Professor Jesús Merayo-Lloves, MD, PhD, DO

Artelac Ectoin improved tear-film stability and key dry-eye symptoms within 28 days

Advertorial: Osmoprotection for a more stable tear film in moderate-to-severe dry eye disease

Artelac Ectoin improved tear-film stability and key dry-eye symptoms within 28 days. Hyperosmolar stress contributes to tear-film instability, ocular-surface damage and inflammatory signalling in dry eye disease. Artelac Ectoin combines 2% ectoine with 0.24% sodium hyaluronate, bringing osmoprotection and lubrication together in one preservative-free drop.^1–4

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Related to this article

(Image credit: Modern Retina; Christina Weng; Amer Alsoudi; Monia Reding) The Retina TL;DR with Dr. Weng: Thriving in retina fellowship with Amer Alsoudi, MD, and Monia Reding, MD

October 23rd, 2026

The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD

In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.

October 23rd, 2026

One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

October 23rd, 2026

A vascular link: erectile dysfunction may signal glaucoma risk in men

An association has been identified between primary open-angle glaucoma and erectile dysfunction.

October 22nd, 2026

Murtaza K. Adam, MD, on pearls for the Yamane scleral-fixated IOL technique

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

October 22nd, 2026

Diabetic macular edema: an inflammatory disease in focus

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

October 21st, 2026

Demodex blepharitis: Diagnosis, treatment response, and recurrence

Himani Goyal, MD, reviews a patient case and discusses what a multispecialty group is seeing in practice.

October 21st, 2026

Brepocitinib meets all Phase 3 end points in noninfectious uveitis

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

(Image credit: Ophthalmology Times) The One Thing: Natural history studies, systemic health, and health care costs | Episode 3

October 21st, 2026

The One Thing: Natural history studies, diet and the gut, and reimbursement | Episode 3

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.

Osmoprotection for a more stable tear film in moderate-to-severe dry eye disease

Related to this article

Trending on Eye Care Network - Ophthalmology Times

Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD

One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia

Brepocitinib meets all Phase 3 end points in noninfectious uveitis

Diabetic macular edema: an inflammatory disease in focus

Murtaza K. Adam, MD, on pearls for the Yamane scleral-fixated IOL technique